NGeneBio Co., Ltd.

medical devices

About

NGeneBio Co., Ltd. is a South Korean company focused on molecular diagnostics and companion diagnostics, particularly in next generation sequencing (NGS)-based in vitro diagnostics. Founded in 2015, the company is headquartered in Seoul and employs around 54 people. NGeneBio develops precision diagnostic products primarily for cancer and genetic disease testing. Key offerings include the BRCAaccuTest™ for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancers, SOLIDaccuTest for solid tumors, and HLAaccuTest for bone marrow transplantation compatibility. The ONCOaccuPanel provides precise diagnoses for large-capacity solid cancers, while the HEREDaccuTest targets rare genetic diseases. NGeneBio also provides clinical analysis software, such as NGeneAnalysis™, which aids in interpreting genetic mutations. Additionally, NGeneBio offers Direct-To-Consumer genetic testing services through a mobile app called "na-e," launched in 2023. The company has achieved significant certifications, including Korea Good Manufacturing Practice (KGMP), and is expanding its global presence through partnerships in various regions.

Technologies

ASP.NET React Native

Keywords

next generation sequencing clinical ngs molecular diagnostics ngs analysis software in vitro diagnostics companion diagnostics brcaaccutest ngeneanalysys ngs ivd cancer diagnostics medical device diagnostics genetic testing medical equipment manufacturing hospital & health care medical devices

Location

Seoul, Seoul, South Korea, 152-050

Related Companies

Companies in the same industry